Gevorg Yaghjyan/LinkedIn
May 20, 2026, 14:13
Gevorg Yaghjyan: Targeting Myostatin in Clinical Trials to Preserve Muscle During Weight Loss
Gevorg Yaghjyan, Project Leader at Parexel, shared a post on LinkedIn:
“Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
GLP-1s deliver weight loss, but trials keep showing a catch: approximately 25-40% of that loss can be lean muscle mass.
Biohaven’s approach: target myostatin in clinical trials to preserve muscle during weight loss.
The hypothesis — better body composition, not just lower weight, drives long-term outcomes.If the data holds, the next obesity trial endpoint might not be pounds lost. It might be muscle retained.
The weight loss race is crowded. The muscle preservation lane is wide open.”
Other posts featuring Gevorg Yaghjyan on Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research